Natamycin
(Synonyms: 纳他霉素; Pimaricin) 目录号 : GC12381
A macrolide polyene antifungal agent
Cas No.:7681-93-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
human corneal epithelial cells(HCE) |
|
Preparation method |
Soluble in DMSO > 10.75 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
5 μM of FITC(Fluorescein isothiocyanate) labelled natamycin for 1 h at 37°C |
|
Applications |
The drug natamycin had a broad spectrum activity against filamentous fungi in the HCE, therefore, it was considered as the drug of choice for the treatment of filamentous fungi associated Keratitis. |
| Clinical experiment [2]: | |
|
Disease models |
Patients with smear positive or culture-positive filamentous fungal corneal ulcers |
|
Dosage form |
5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks |
|
Application |
Topical natamycin was superior to topical voriconazole for the treatment of filamentous fungal corneal ulcers, and in particular those culture-positive for Fusarium species. Vision-related functioning was higher among those treated with natamycin compared with voriconazole. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Jain A1, Shah SG, Chugh A, Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis. Pharm Res. 2015 Jun;32(6):1920-30. doi: 10.1007/s11095-014-1586-x. Epub 2014 Dec 3. [2]. Rose-Nussbaumer J1,2,3, Prajna NV4, et al, Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole. Br J Ophthalmol. 2016 Jul;100(7):929-932. doi: 10.1136/bjophthalmol-2015-306828. Epub 2015 Nov 3. |
|
[1]. Lalitha, P., Vijaykumar, R., Prajna, N.V., et al. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: Comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. Journal of Clinical Microbiology 46(10), 3477-3478 (2008).
[2]. te Welscher, Y.M., ten Napel, H.H., Balagué, M.M., et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. The Journal of Biological Chemisty 283(10), 6393-6401 (2008).
[3]. Dong, X.H., Gao, W.J., and He, X.P. Antifungal efficacy of natamycin in experimental fusarium solani keratitis. Int.J.Ophthalmol. 5(2), 143-146 (2012).
[4]. de Vries, R.P., de Lange, E.S., Wösten, H.A.B., et al. Control and possible applications of a novel carrot-spoilage basidiomycete, Fibulorhizoctonia psychrophila. Antonie Van Leeuwenhoek 93, 407-413 (2008).
| Cas No. | 7681-93-8 | SDF | |
| 别名 | 纳他霉素; Pimaricin | ||
| 化学名 | (5R,7R,24S)-22R-[(3S-amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-1R,3S,26S-trihydroxy-12R-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8E,14E,16E,18E,20E-pentaene-25R-carboxylic acid | ||
| Canonical SMILES | O[C@](C1)(C[C@H](C[C@H]2O[C@@H]2/C=C\C(O[C@H](C)C/C=C\C=C/C=C\C=C/[C@@H]3O[C@@H]([C@H]([C@H]4N)O)O[C@H](C)[C@H]4O)=O)O)O[C@](C3)([H])[C@H](C(O)=O)[C@H]1O | ||
| 分子式 | C33H47NO13 | 分子量 | 665.73 |
| 溶解度 | ≥ 16.425mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5021 mL | 7.5106 mL | 15.0211 mL |
| 5 mM | 0.3004 mL | 1.5021 mL | 3.0042 mL |
| 10 mM | 0.1502 mL | 0.7511 mL | 1.5021 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。